Okada R, Otsuka Y, Wakabayashi T, et al. - In this multicenter study, researchers assessed the diagnostic and prognostic ability of six autoantibodies against a panel of six hepatocellular carcinoma (HCC)‐associated antigens, including Sui1, p62, RalA, p53, NY‐ESO‐1 and c‐myc, given that serum autoantibodies have been said to react with tumor‐associated antigen (TAA) in different cancers. From six institutions, 160 patients with HCC and 74 healthy controls were prospectively recruited. Data reported that the sensitivities were 19% for Sui1, 18% for p62, 17% for RalA, 11% for p53, 10% for NY‐ESO‐1 and 9% for c‐myc. The TAA panel's overall sensitivity, at 56%, was higher than α‐fetoprotein's. Positivity for the TAA panel was independently linked to poor prognosis, in multivariate analysis. In HCC patients, there may be diagnostic and prognostic value in this TAA panel.